SecBot SecBot
8-K ·Filed May 5, 2026

ALKS

Alkermes plc.
MIXED
Impact 5/10
Horizonweeks Processed6mo ago SEC0001193125-26-205008
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The Avadel acquisition is transforming the revenue base but depressing GAAP earnings due to non-cash charges. Monitor LUMRYZ sales trajectory and integration costs in Q2; the improved GAAP net loss guidance suggests cost synergies are tracking ahead of plan. The maintained Adjusted EBITDA guidance of $370M-$410M provides a clean view of underlying cash generation.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$36.23
T+0 close · May 5, 2026 · via day close
Latest settled
+38.10%
T+60 · $50.03
Vs SPY
+35.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $36.23entry
  2. T+1 · 7mo ago −2.87%α −4.26% · $35.19
  3. T+5 · 6mo ago +5.60%α +3.62% · $38.26
  4. T+20 · 6mo ago +14.06%α +9.10% · $41.32
  5. T+60 · 4mo ago +38.10%α +35.63% · $50.03

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alkermes reported Q1 2026 revenue of $392.9M, up 28% YoY, driven by the Avadel acquisition adding LUMRYZ ($39.5M) and strong growth in LYBALVI (+32%). GAAP net loss was $66.5M vs. $22.5M income a year ago, reflecting acquisition-related costs and higher R&D/SG&A. The company narrowed its FY 2026 GAAP net loss guidance to ($70M)-($90M) from ($115M)-($135M) on lower expected COGS and amortization, while maintaining revenue and Adjusted EBITDA guidance.

Key Financial Metrics

EPS
−$0.40
est −$0.57 · +29.8%
Revenue
$392.9M
est $361.4M · +8.7% · +28.2% YoY
Rating
in line
Guidance
$1.73B-$1.84B
maintained

Key Facts

  • Q1 2026 total revenue $392.9M, up 28% YoY from $306.5M
  • GAAP net loss of $66.5M vs. net income of $22.5M in Q1 2025
  • GAAP diluted EPS of ($0.40) vs. $0.13 in Q1 2025
  • Adjusted EBITDA of $80.3M, up 76% from $45.6M in Q1 2025
  • LYBALVI revenue $92.4M, up 32% YoY; prescriptions up 21%
  • LUMRYZ contributed $39.5M in first 6 weeks post-Avadel acquisition
  • FY 2026 revenue guidance maintained at $1.73B-$1.84B
  • FY 2026 GAAP net loss guidance improved to ($70M)-($90M) from ($115M)-($135M)
  • FY 2026 Adjusted EBITDA guidance maintained at $370M-$410M
  • Share repurchases of ~1M shares for $28M in Q1; $172M remaining under program

Financial Impact

Revenue growth of 28% YoY to $392.9M, but GAAP net loss of $66.5M driven by $55.8M in Avadel acquisition costs and $54.6M in share-based compensation

revenueepsebitdadebt

Risk Factors

  • Integration of Avadel may face execution risks; $1.525B in new term loans increases leverage
  • LUMRYZ faces competition from Jazz Pharma's Xyrem/Xywav; market share trajectory is key
  • R&D spending up 44% YoY to $103.3M as Phase 3 alixorexton program ramps up
  • GAAP net loss expected for full year 2026 despite strong revenue growth

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-205008
Document: alks-20260505.htm0001193125-26-205008
Document: alks-ex99_2.htm0001193125-26-205008
Document: 0001193125-26-205008-index-headers.html0001193125-26-205008
Document: 0001193125-26-205008-index.html0001193125-26-205008
Document: 0001193125-26-205008.txt0001193125-26-205008
8-K Data (Synthetic)0001193125-26-205008

Track record

23 reports on ALKS

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.88% at T+60 after the May 12, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $46.98 Now $46.53 −0.96% settles Feb 10
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $44.54 Now $46.53 +4.47% settles Feb 3
  3. Nov 3, 202613d ago 144 Neutral 2/10 Entry $45.89 Now $46.53 +1.39% settles Feb 2
  4. Nov 3, 202613d ago 8-K Neutral 5/10 Entry $45.69 Now $46.53 +1.84% settles Feb 1
  5. Sep 21, 20268w ago 8-K Bullish 6/10 Entry $44.00 Now $46.53 +5.76% settles Dec 15
  6. Sep 16, 20268w ago 8-K Neutral 2/10 Entry $46.07 Now $46.53 +1.00% settles Dec 10
  7. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $46.10 Now $46.53 +0.93% settles Dec 1
  8. Aug 3, 202615w ago Insider Cluster Bearish 4/10 Entry $49.67 to $44.32 Now $46.53 +6.32% ▲ +10.77% +11.15% vs SPY
  9. Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
  10. Aug 3, 202615w ago Insider Cluster Neutral 3/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (10h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026